Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

@article{Michallet2000TransplantationWS,
  title={Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.},
  author={Mauricette Michallet and Thomas Philip and Ir{\`e}ne Philip and Hubert Godinot and Catherine J Sebban and Gilles Salles and Anne C. M. Thi{\'e}baut and Pierre Eymard Biron and Francisco Zamora L{\'o}pez and Philippe Mazars and Nora Roubi and Thomas Leemhuis and Edith A.S. Hanania and Chris Reading and Gil David Fine and Kerry M Atkinson and Clemens Juttner and Bertrand Coiffier and Denis Fi{\`e}re and Eric Archimbaud},
  journal={Experimental hematology},
  year={2000},
  volume={28 7},
  pages={
          858-70
        }
}
OBJECTIVE The aims of our study performed in myeloma were to evaluate the performance and the safety of Systemix's high-speed clinical cell sorter, to assess the safety and efficacy of deescalating cell dose cohorts of CD34+Thyl+ hematopoietic stem cells (HSCs) as autologous grafts by determining engraftment, and to assess the residual tumor cell contamination using polymerase chain reaction (PCR) amplification assays of patient-specific complementarity determining region III (CDR III) analysis… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 39 CITATIONS

Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem Cells.

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2017

How One Thing Led to Another.

  • Annual review of immunology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND